Q BioMed (Q BioMed) FCF Margin % : 0.00% (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Q BioMed's Free Cash Flow for the three months ended in Feb. 2023 was $-0.14 Mil. Q BioMed's Revenue for the three months ended in Feb. 2023 was $0.00 Mil. Therefore, Q BioMed's FCF Margin % for the quarter that ended in Feb. 2023 was 0.00%.

As of today, Q BioMed's current FCF Yield % is 0.00%.

The historical rank and industry rank for Q BioMed's FCF Margin % or its related term are showing as below:

QBIO' s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1043.54
Current: 1043.54

During the past 10 years, the highest FCF Margin % of Q BioMed was 1043.54%. The lowest was 0.00%. And the median was 0.00%.

QBIO's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -141.08 vs QBIO: 1043.54

Q BioMed FCF Margin % Historical Data

The historical data trend for Q BioMed's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed FCF Margin % Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

FCF Margin %

Get a 7-Day Free Trial

-20,776.67

-2,194.90

683.45

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
FCF Margin %	Get a 7-Day Free Trial															-502.67	-64.71	-919.23	20,523.08	-

Competitive Comparison of Q BioMed's FCF Margin %

For the Biotechnology subindustry, Q BioMed's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Q BioMed's FCF Margin % falls into.

Q BioMed FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Q BioMed's FCF Margin for the fiscal year that ended in Nov. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Nov. 2022 )	/	Revenue (A: Nov. 2022 )
	=	1.941	/	0.284
	=	683.45 %

Q BioMed's FCF Margin for the quarter that ended in Feb. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Feb. 2023 )	/	Revenue (Q: Feb. 2023 )
	=	-0.138	/	0
	=	%

Q BioMed FCF Margin % Related Terms

Thank you for viewing the detailed overview of Q BioMed's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1